POU class 4 homeobox 2Genealiases: BRN3.2 · BRN3B · Brn-3b
Q-omics provides the consensus-scored POU4F2 profile across patient tissues and cancer cell-line models. POU4F2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, POU4F2 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, POU4F2 RNA expression shows 5,637 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SCLC, THCA, and STAD as cancer lineages where POU4F2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POU4F2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POU4F2 survival associations across molecular data types. POU4F2 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POU4F2 RNA expression–survival associations across cancer types. High POU4F2 expression shows unfavorable associations in ACC, MESO, THCA and READ, but favorable associations in SCLC and PAAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for POU4F2 RNA expression.
This table summarizes POU4F2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for POU4F2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POU4F2 shows lower tumor expression in PRAD, COAD and UCEC and higher tumor expression in THCA and ESCA. The THCA box plot shows higher POU4F2 RNA expression in tumor versus normal tissue (log2 FC = +0.004, t-test p = .012).
This table shows molecular features associated with POU4F2 in patient tissues and cancer cell lines. In patient samples, POU4F2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, POU4F2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
